MSCL — Satellos Bioscience Income Statement
0.000.00%
Last trade - 00:00- CA$104.47m
- CA$34.62m
- 39
- 26
- 41
- 28
Annual income statement for Satellos Bioscience, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.65 | 15.6 | 11.4 | 15.9 | 31.8 |
| Operating Profit | -1.65 | -15.6 | -11.4 | -15.9 | -31.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.49 | -15.5 | -11.3 | -15.9 | -28.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.49 | -15.5 | -11.3 | -15.9 | -28.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.49 | -15.5 | -11.3 | -15.9 | -28.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.49 | -15.5 | -11.3 | -15.9 | -28.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.194 | -0.237 | -0.265 | -0.179 | -0.21 |